INVO Fertility on Thursday reported second-quarter earnings that exceeded expectations, with adjusted profit per share rising above estimates, though revenue lagged behind projections.
The fertility services provider posted adjusted earnings of $1.05 per share, surpassing the $0.85 per share forecast by analysts surveyed by Refinitiv. Revenue for the period totaled $112.3 million, missing the $118.7 million estimate.
The company attributed the earnings beat to operational efficiencies and cost management, which offset softer revenue growth in certain service lines. INVO Fertility’s core business, which includes in vitro fertilization and related fertility treatments, saw demand remain stable but pricing pressures weighed on top-line performance.
Management reaffirmed its full-year guidance, citing confidence in sustained demand for fertility services despite macroeconomic headwinds. The company expects revenue growth to accelerate in the second half, supported by expansion in its service offerings and geographic reach.
Analysts noted that while the earnings beat provides a near-term positive signal, the revenue shortfall underscores ongoing challenges in a competitive healthcare market. INVO Fertility’s stock was little changed in extended trading following the release.
